home / stock / clrb / clrb news

CLRB News and Press, Cellectar Biosciences Inc. From 07/21/20

Stock Information
Company Name: Cellectar Biosciences Inc.
Stock Symbol: CLRB
Market: NASDAQ
Website: cellectar.com
Menu
CLRB CLRB Quote CLRB Short CLRB News CLRB Articles CLRB Message Board
Get CLRB Alerts

News, Short Squeeze, Breakout and More Instantly...
CLRB - Cellectar Announces Poster Presentation of Clinical Data at the American Association of Cancer Research (AACR) Annual Meeting

FLORHAM PARK, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a poster presentation at the up...
CLRB - NIO, BLDP among premarket gainers

LM Funding America (NASDAQ: LMFA ) +83% . More news on: LM Funding America, Inc., Myomo, Inc., Electrameccanica Vehicles Corp., Stocks on the move, , Read more ...

CLRB - Cellectar Appoints Dr. John Friend as Chief Medical Officer

FLORHAM PARK, N.J., July 01, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has appointed Dr. John ...

CLRB - INO, PEI among premarket gainers

Fuwei Films (NASDAQ: FFHL ) +66%  on Q1 results . More news on: Fuwei Films (Holdings) Co., Ltd., Translate Bio, Inc., Recon Technology, Ltd., Stocks on the move, , Read more ...

CLRB - Cellectar Bio nabs another European patent covering lead candidate

The European Patent Office issues a composition of matter  patent to Cellectar Biosciences ( CLRB -5.8% ) covering the use of phospholipid ether (PLE) analogs as cancer-targeting drug vehicles. More news on: Cellectar Biosciences, Inc., Healthcare stocks news, Read more ...

CLRB - Cellectar to be Granted EU Patent for Phospholipid Ether (PLE) Analogs as Cancer-Targeting Drug Vehicles

FLORHAM PARK, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the European Patent Office...

CLRB - NetworkNewsBreaks - Cellectar Biosciences, Inc. (NASDAQ: CLRB) Secures $20.0M in Underwritten Public Offering

Cellectar Biosciences (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, has closed an underwritten public offering for gross proceeds of $20.0 million. According to the update, the offeri...
CLRB - M, OPK among premarket gainers

IZEA Worldwide (NASDAQ: IZEA ) +79% . More news on: IZEA Worldwide, Inc., Second Sight Medical Products, Inc., Immuron Limited, Stocks on the move, , Read more ...

CLRB - Cellectar Bio closes $20M capital raise

Cellectar Biosciences (NASDAQ: CLRB ) has closed its public offerin g of ~14.6M common shares and accompanying Series H warrants to purchase ~8.7M shares at $1.2075. It also issued ~2.8M pre-funded warrants. More news on: Cellectar Biosciences, Inc., Healthcare stocks news, , Stocks on th...

CLRB - Cellectar Biosciences Announces Closing of $20 Million Underwritten Public Offering

FLORHAM PARK, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the closing of its previously announced un...
Previous 10 Next 10